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Abstract 
 Age-related neurodegeneration in the brain and retina is complicated. It comprises a 
series of events encompassing different modes of degeneration in neurons, as well as 
inflammation in glial cells. Systemic inflammation and risk factors can contribute to disease 
progression. Age-related conditions such as Alzheimer’s disease (AD), Parkinson’s disease (PD) 
and Age-related Macular Degeneration (AMD) affect patients for 5 to 20 years and are highly 
associated with risk factors such as hyperhomocysteinæmia, hypercholesterolæmia, hypertension, 
and symptoms of mood disorder. The long duration of the degeneration and the wide array of 
systemic factors provide the opportunity for nutraceutical intervention to prevent or delay disease 
progression.  
 Small molecules such as phenolic compounds are candidates for neuroprotection because 
they have anti-oxidant activities and can modulate intracellular signaling pathways. Bigger 
entities such as oligosaccharides and polysaccharides have often been neglected because of their 
complex structure. However, certain big molecules can provide neuroprotective effects. They 
may also have a wide spectrum of action against risk factors.  
 In this review we use an integrative approach to the potential uses of nutraceutical 
products to prevent age-related neurodegeneration. These include direct effects of phenolic 
compounds and polysaccharides on neurons to antagonize various neurodegenerative 
mechanisms in AD, PD and AMD, and indirect effects of these compounds on peripheral 
disease-related risk factors. 
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1.  INTRODUCTION 
 Aging is a major risk factor contributing to the onset and progression of many 
neurodegenerative diseases. Although the symptoms, pathological changes and even the regions 
being affected during the neurodegenerative process are diverse, it is certain that these diseases 
share many common factors. Numerous studies demonstrate that oxidative stress, chronic 
inflammation, impairment of protein processing and degradation, and alterations of cellular 
survival pathways are common features of age-associated neurodegenerative diseases. These 
stress factors are therefore potential targets for disease prevention and intervention.  
 Nutraceutical intervention may be an effective mean for the prevention of age-associated 
neurodegenerative diseases. Certain diets reportedly reduce the risk of neurodegenerative 
diseases [1-4]. In this paper we review the current concepts of three age-related 
neurodegenerative diseases: Alzheimer’s disease (AD), Parkinson’s disease (PD), and Age-
related Macular Degeneration (AMD), and summarize common therapeutic strategies. We also 
discuss the feasibility of several small phenolic compounds or big molecules such as 
oligosaccharides, polysaccharides and glycoconjugates from plant and marine sources as agents 
to intervene with the above illnesses.  
2. AGE-RELATED NEURODEGENERATIONS: UNIQUE SYMPTOMS AND 
COMMON PATHOGENIC MECHANISMS 
2.1 Unique features in Alzheimer’s disease (AD), Parkinson’s disease (PD), and Age-related 
Macular Degeneration (AMD) 
 AD is the leading cause of dementia. It is characterized by a decline in short-term 
memory and a slowly progressive loss of other cognitive functions. The unique pathological 
hallmarks of AD are the accumulation of extracellular senile plaques and intraneuronal 
neurofibrillary tangles (NFTs) in the hippocampus and cerebral cortex. Senile plaques and NFTs 
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are made up of aggregated amyloid- (A) peptide and hyperphosphorylated tau (p-tau) protein, 
respectively [5]. 
 PD is characterized by movement difficulties including tremor, bradykinesia, and rigidity 
at early stages. At late stages, cognitive and behavioral impairment may arise. The substantia 
nigra in the midbrain is the major area affected, with massive loss of dopaminergic neurons 
accompanied by intracellular Lewy body inclusions. α-Synuclein is the major component of 
Lewy bodies [6].  
 AMD is one of the leading causes to severe visual impairment in the elderly [7, 8] and is 
ranked as the third cause of blindness [9]. It is categorized into dry or wet forms, which are 
characterized by derangement and detachment of the retinal pigment epithelium and visible 
choriocapillaris [10, 11], or abnormal in-growth of blood vessels into the retina concomitant with 
subretinal hæmorrhage, respectively [12, 13]. AMD is a chronic degeneration of photoreceptors 
and retinal pigment epithelium of the macular region of the retina [14, 15]. Drusen in the macula 
are the major pathogenic factor. Drusen are yellow deposits containing oxidized products, 
immunoregulators, Aβ assemblies and cell debris [16]. 
 
2.4 Similarities in neurodegenerative mechanisms, risk factors and therapeutic strategies 
among AD, PD and AMD 
 The neurodegenerative mechanisms of AD, PD, AMD are found to be quite similar. 
Although debate continues on whether senile plaques, NFTs, Lewy bodies or drusen are 
responsible for the initiation of neurodegeneration in the diseases, large bodies of evidence from 
cell culture and animal studies show that these aggregated proteins are associated with 
neuroinflammation, oxidative stress and activation of stress or pro-apoptotic signaling pathways 
[17-19]. Targeting these common neurodegenerative mechanisms with the use of anti-oxidant, 
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anti-inflammatory drugs and specific stress signal inhibitors can therefore provide beneficial 
effects for disease prevention or treatment. Anti-oxidants are perhaps the most-investigated 
disease-modifying agents. In human subjects, anti-oxidant intervention with vitamin E is 
associated with better cognitive performance and may reduce the risk of AD [20-22]. For PD, 
anti-oxidants have shown protective effects in different experimental models [23-25]. Anti-
oxidants may also benefit AMD. A diet with a high content of carotenoids such as vitamin A, 
lutein, and zeaxanthin has been recommended [26]. Together with supplements of antioxidants 
such as vitamin C and E, a cocktail of antioxidants reportedly prevents progression of AMD to 
late stage [27]. The use of anti-inflammatory drugs has been investigated in various diseases. 
Epidemiological studies suggest that non-steroid anti-inflammatory drugs (NSAIDs) may reduce 
the risk of AD [28]. However, the use of NSAIDs in AD is now quite controversial as several 
clinical trials demonstrate the ineffectiveness of NSAIDs for slowing the progression of AD [29, 
30]. It is yet too early to conclude that anti-inflammatory drugs are ineffective for AD treatment 
or prevention as the dosage and duration of drug between epidemiological and clinical studies are 
different [31]. Nevertheless, down-regulation of cerebral inflammation is still a major target to 
retard disease progression [32, 33]. In PD, anti-inflammation has long been a major thrust in drug 
development [34]. In AMD, complement-mediated inflammation is involved in the pathogenesis, 
hence complement inhibition has been suggested as a potential pharmacological approach for 
disease treatment [35]. 
 Age-related neurodegenerative diseases are often multifactorial and are associated with a 
number of risk factors. For example, AD is associated with smoking [36], diabetes mellitus [37] 
and hypertension [38]. PD is associated with hyperhomocysteinaemia [39] and exposure to 
pesticides [40]. AMD is associated with smoking, excessive light exposure and other attributed 
causes [41]. There are lots of overlapping of factors leading to disease progression and 
pathogenesis among these three neurodegenerative diseases. For example, cognitive impairment 
can occur in the late stage of PD [42]. Risk factors for AMD and AD are very similar [43, 44]. 
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Aβ peptides have been found in AMD drusen [45, 46], and anti-Aβ therapy may be a strategy for 
AMD [47]. Some common risk factors for AD, PD and AMD are summarized in Table 1. In 
view of these, it is possible that some bioactive food compounds may reduce risk and modulate 
the pathogenesis of AD, PD and AMD indirectly. 
3. NUTRACEUTICAL INTERVENTION FOR AGE-RELATED 
NEURODEGENERATIVE DISEASES 
3.1 Polyphenols  
Polyphenols is a class of highly bioactive compounds characterized by multiple hydroxyl 
groups attached to aromatic rings. Based on the number of phenol rings, how the rings are 
connected, and the chemical groups attached, polyphenolic compounds can be categorized into 
flavonoids, stilbenes, phenolic acids, phenolic alcohols, and lignans [48, 49]. They can either be 
naturally occurring as plant secondary metabolites, or synthesized by chemical means [49]. A 
number of in vitro and in vivo studies have demonstrated that these small molecules are able to 
modulate many pathways for disease progression and cellular survival in addition to their strong 
antioxidant, anti-inflammatory, and vasodilatory effects [25, 50]. All these properties can 
potentially combat common stress factors in many neurodegenerative diseases and thus be 
neuroprotective. In this section we mainly focus on the flavonoids and stilbenes because they 
have been well studied for their neuroprotective roles. 
3.1.1 Flavonoids 
 Flavonoids are ubiquitous in plants and make up one of the largest subclasses of 
polyphenols [49]. They are characterized by a common structure (Figure 1a) formed by two 
benzene rings (rings A and B) interconnected by a 3-carbon oxygenated heterocycle (ring C) [48]. 
They can be further subdivided into flavonols, flavanols, flavones, isoflavones, flavanones, and 
anthocyanidins upon the saturation of ring C, the presence or absence of the 4-oxo-function, and 
the chemical substitutions on the B and C rings (Figure 1b) [51]. In food and beverages, 
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flavonoids are often glycosylated, linked to organic acids, and/or to one another [49]. The daily 
intake of flavonoids is highly variable among different ethnic groups, ranging from 20 to 1000 
mg per day [52].  
(A) Anti-oxidative effects of flavonoids and their structures 
 Many investigators have emphasized the antioxidant properties of flavonoids in relation 
to their neuroprotective effects. Accordingly, flavonoids can directly interact with reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) [53], chelate transition metals such as 
iron and copper to suppress metal-catalyzed oxidative stress via the Fenton reaction [54], boost 
intracellular antioxidant enzyme activities [55], and preserve endogenous antioxidants [56, 57]. 
For example, a flavanol abundantly found in green tea, epigallocatechin-3-gallate (EGCG; Figure 
2a), and a flavonol highly present in onions and apples, quercetin (Figure 2b), can directly 
quench singlet oxygen and scavenge hydroxyl radicals, superoxide radicals, and lipid peroxyl 
radicals by donating hydrogen [51, 53, 55].  
 An analysis of structure and antioxidant activity relationships among various flavonoid 
subclasses reveals that certain structural features give rise to better antioxidant capabilities, 
including (1) the presence of ortho-dihydroxy groups in ring B, (2) the combination of 2,3 
carbon-carbon double with the 4-oxo function in ring C, and (3) the possession of the 3-OH and 
5-OH groups with the 4-oxo function on the A and C rings [51, 53]. Quercetin (Figure 2b) bears 
all the above features and is thus a strong antioxidant. In general, these characteristics allow 
greater electron delocalization and stability after donation of hydrogen. Regarding iron and 
copper chelating properties, three structural sites have been proposed to be responsible for 
forming inactive complexes with metals. These are (1) the ortho-hydroxy groups in ring B, (2) 
the 4 oxo-function together with 3-OH or 5-OH in rings A and C [51], and (3) the ortho-hydroxy 
group in gallic side chain as in EGCG [55, 58]. In addition, EGCG up-regulates the activities of 
the antioxidant enzymes catalase (for H2O2) and superoxide dismutase (for superoxide) in the 
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striatum of experimental mice [59], whereas quercetin can prevent the oxidation of the 
endogenous antioxidant glutathione in neurons [56, 57], thereby indirectly combating oxidative 
stress. 
(B) Signaling pathways regulated by flavonoids 
 Besides antioxidant mechanisms, flavonoids function as regulators of many cellular 
pathways such as phosphoinositide-3-kinase (PI3K)-Akt/protein kinase B (Akt/PKB) and 
mitogen-activated protein kinase (MAPK) pathways for neuroinflammation, neuronal survival 
and vasodilation [50]. For instance, EGCG suppressed the expression of cyclooxygenase-2 
(COX-2) and inducible nitric oxide synthase (iNOS) and the release of nitric oxide (NO) and pro-
inflammatory cytokines from astrocytes and microglia by inhibiting MAPK signaling cascades 
[60]. EGCG-mediated phosphorylation of protein kinase C (PKC) promotes survival of human 
neuroblastoma SH-SY5Y cells from Aβ and 6-hydroxydopamine (6-OHDA)-induced 
neurotoxicity, increases proteasomal removal of pro-apoptotic Bad protein, and shifts amyloid 
precursor protein (APP) processing to the non-amyloidogenic α-secretase pathway [61]. On the 
other hand, quercetin protects neurons against hydrogen peroxide and tumor necrosis factor-α 
(TNF-α)-induced neuronal death by inhibiting c-Jun N-terminal kinase (JNK) [50]. Naringenin 
(Figure 2c), a flavanone with high abundance in citrus fruits, protects neurons against bacterial 
endotoxin lipopolysaccharides (LPS) in combination with -interferon (IFN-)-induced glial 
activation by suppressing p38 and signal transducers and activators of transcription family of 
transcription factor 1 (STAT1) [62]. As for vasodilatory effects, Sorond et al demonstrated that 
consumption of a flavanol-rich cocoa drink for 1-2 weeks increased cerebral blood flow in the 
middle cerebral artery in healthy elderly subjects, presumably by increasing NO availability [63]. 
This may provide therapeutic benefits to AD and PD patients, in which a reduction in cerebral 
blood flow had been reported. 
3.1.2 Stilbenes 
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The basic structure of stilbenes comprises a 1,2-diphenylethylene backbone with the two 
phenyl groups arranged in either cis or trans configuration (Figure 3). Both isomers can optically 
interconvert via a singlet-electron excited state, and the trans isomer is generally more stable [64]. 
Stilbenes exist as monomers, dimers, and oligomers [65]. Unlike flavonoids, in which the 
neuroprotective capacities of various subgroups have been investigated, research on stilbenes has 
mostly focused on resveratrol and its structural analogues.  
(A) Reservatrol as a naturally occur stilbene derivative 
 Reservatrol (Figure 4a) is a stilbene derivative naturally synthesized on the skins of 
grapes in response to fungal invasion, but is also present in wine, peanuts, and berries [66]. It has 
been considered to be the chief ingredient responsible for the health-promoting effects of red 
wine, and a great number of in vitro and animal models have shown that it could potentially elicit 
multiple benefits in retarding neurodegenerative processes [23, 67-70], diabetes [71, 72], cancer 
[73-75], and cardiovascular diseases [76, 77]. In addition, several interesting articles have been 
published on the pharmacokinetics of orally administered resveratrol in humans [78-83] 
(B) Anti-oxidative effects of resveratrol 
Like the flavonoids, resveratrol bears good antioxidant, anti-inflammatory, vasoactive, and 
pro-survival effects, making it a candidate to counteract the common stress factors for age-
related neurological disorders [25]. Resveratrol directly scavenges hydroxyl radicals, superoxide, 
and DPPH. radicals in cell-free systems [84, 85], and inhibits H2O2- or lipid peroxide-dependent 
peroxidation of membrane lipids in culture [86]. Based on a structural comparison of resveratrol 
and its analogues, it was deduced that the 4'OH served as the most important hydrogen donation 
site [85], and that monohydroxystilbenes such as piceatannol and oxyresveratrol, and 
polyhydroxystilbenes such as hexahydroxystilbene (also known as M8), were significantly more 
effective radical scavengers than resveratrol [66]. Since resveratrol is largely present in 
conjugated forms in the body [87], caution should be exercised when extrapolating such 
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structural relationship and radical scavenging activities in vivo. Intraperitoneal injection of 
resveratrol up-regulates endogenous antioxidant enzymes in the brain, including superoxide 
dismutase, peroxidase, and catalase [88].  
(C) Anti-inflammatory effects of resveratrol 
 Resveratrol is a non-specific COX-1 and COX-2 inhibitor [19, 87]. COX-1 is 
constitutively active for prostaglandin E synthesis and its inhibition has been regarded as 
unfavourable, whereas selective suppression of COX-2 activity is the target of many NSAIDs 
[89]. Attempts have been made to chemically modify resveratrol by adding one or more hydroxyl 
groups so that it will act as a selective COX-2 inhibitor. For example, both piceatannol (Figure 
4b) and hexahydroxystilbene (Figure 4c), which are monohydroxylated and polyhydroxylated 
stilbenes respectively, are selective COX-2 inhibitors and may be superior to resveratrol in 
fighting neuroinflammation [66].  
(D) Beneficial effects of resveratrol on neurons of AD and PD 
Resveratrol exhibits pro-survival effects both in vitro and in vivo. For example, it activates 
the sirtuin protein SIRT1, a NAD+-dependent histone deacetylase protein in vitro [90]. In mouse 
models of AD a calorie-restricted diet reduces AD pathogenesis via an increase in SIRT1 
activity [87]. In yeast, induction of a homologue of SIRT1 (SIR2) helps to prolong lifespan. 
These reports suggest that SIRT1 is a key factor to prolong survival of neurons [61]. SIRT1 
over-expression reduces Aβ pathology in APP-expressing neuronal cultures by hindering 
intracellular Aβ peptide synthesis [67, 91]. On the other hand, resveratrol stimulates the removal 
of intracellular Aβ in different cell lines through proteasomal degradation [24]. In models of PD, 
resveratrol inhibits dopamine-induced cell death in dopaminergic SH-SY5Y cells by up-
regulating anti-apoptotic Bcl-2 and down-regulating caspase 3 [69, 92], and oral administration 
of resveratrol attenuates 6-OHDA-induced dopamine depletion and loss of dopaminergic 
neurons in rats [23].  
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(E) Regulation of cerebrovascular functions by resveratrol 
In addition to its role in cardiovascular health resveratrol improves cerebral blood flow, 
which may alleviate complications in AD and PD. For example, Lu and colleagues have shown 
that a single intravenous injection of resveratrol (20 mg/kg) elevated hippocampal blood flow 
by NO-dependent mechanisms during cerebral ischemia induced by coronary artery ligation 
[93]. Oral administration of resveratrol to healthy human adults dose-dependently improved 
cerebral blood flow in the frontal cortex during specific cognitive performance tasks [94].  
3.2 Big molecules as potential neuroprotective agents for aged-related neurodegeneration 
  Increasing lines of evidence have shown that big molecules such as polysaccharides and 
glycoconjugates exhibit diverse biological activities [95-97]. It is now known that the 
progression of neurodegenerative disease can be influenced by systemic as well as CNS factors. 
In this section, we focus on polysaccharides that have potential neuroprotective effects. We also 
include some synthetic derivatives of polysaccharides. Since the structures of these ‘big 
molecules’ are more complicated than those of small molecules, it is sometimes difficult to 
correlate their biological actions with their specific structures. We summarize the data regarding 
their direct protective effects on neurons, indirect effects on disease-related risk factors, and 
immunomodulation properties. We use several examples to illustrate how these big molecules 
could modulate the progression of neurodegenerative diseases directly and indirectly. 
3.2.1 Direct effects on neurons 
(A) Chitosan and its derivatives – oligosaccharides from marine sources 
 Chitosan and its derivatives are polysaccharides or glycans that exhibit direct protective 
effects on neurons. Chitosan can be produced by deacetylation of chitin, a natural occurring 
polysaccharide which is abundant in the exoskeleton of marine organisms such as crabs [98]. It 
has poor solubility. Hydrolysis converts it to chito-oligosaccharides (COSs).  
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 COSs protect rat hippocampal neurons from glutamate-induced toxicity [99], which 
accelerates disease progression in different neurodegenerative diseases. COSs dose-dependently 
reduces the levels of apoptotic cell death-triggered by glutamate in cultured hippocampal neurons.  
COS treatment attenuates calcium influx and caspase-3 activation [99]. COSs might provide 
neuroprotection through their anti-oxidant actions. This is feasible because COSs have hydroxyl 
and superoxide radical scavenging properties [100]. They also reduce production of NO in a 
human melanoma cell line (B16F1) stimulated by LPS, and down-regulate the expression of the 
NF-κB gene in B16F1 cells exposed to hydrogen peroxide [101]. In copper-treated primary 
cultures of cortical neurons, COSs reduce the levels of ROS. Copper-induced toxicity has been 
implicated in a number of neurodegenerative diseases, including AD [102].    
 Neuroinflammation is involved in AD, PD and AMD, and attenuation of inflammatory 
responses is a potential therapeutic strategy. Neuroinflammation can be induced by agents such 
as A peptide and pro-inflammatory cytokines. Chitosan exhibits anti-inflammatory activities. 
Kim and colleagues reported that A peptide and the cytokine interleukin-1 (IL-1) could induce 
cultured astrocytes to secrete the pro-inflammatory cytokines TNF- and IL-6. This was 
attenuated by treatment with a water-soluble chitosan. The levels of iNOS were also attenuated in 
the chitosan-treatment groups [103].  
 Apart from non-specific actions against neurodegeneration (anti-oxidant, anti-
neuroinflammation and anti-glutamate-induced toxicity), COSs and chitosan exhibit specific 
effects in particular neurodegenerative diseases. COSs and chitosan derivatives may elicit 
protective effects against AD by affecting the production of A peptide and inhibiting 
acetylcholinesterase (AChE) activity. The production of A from its precursor APP heavily 
depends on the activity of -secretase, also known as -amyloid cleavage enzyme (BACE-1). In 
vitro data suggest that COSs and chitosan derivatives are BACE-1 inhibitors [104, 105]. Joe and 
colleagues modified the structure of chitosan by performing amino-alkylation on chitosan and 
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replaced the hydroxyl group by an amino-alkyl group, and tested the resultant water soluble 
chitosan derivatives for BACE-1 inhibitory activity. Among the three derivatives tested, 
aminoethyl-chitosan was the strongest BACE-1-inhibitor. After structural comparison of the 
derivatives, they suggested that the free amino group at the C-2 and C-6 positions played an 
important role in the BACE-1 inhibitory activity [105]. The same group also conducted studies 
on COSs. They found that a 90% deacetylated COSs derivative provided the strongest BACE-1 
inhibitory activity, and that deacetylation and sulfation at the C-2 position could affect the 
biological activities of COSs [104]. Lee and colleagues demonstrated the importance of 
deacetylation for anti-AChE activity. Acetylcholine (ACh) is an important neurotransmitter 
which is ablated in AD; ACh levels can be maintained by inhibiting its degrading enzyme AChE. 
COSs derivatives show different degrees of AChE inhibition. The degree of deacetylation had 
major effects on the anti-AChE properties, and can transform COS from a non-competitive to a 
competitive AChE inhibitor [106]. 
(B)  Lycium barbarum polysaccharide – the ‘sugar’ from berry  
 The fruits of Lycium barbarum, which are also called Wolfberry, are common herbs and 
foods in Asian countries. L. barbarum polysaccharides (LBP) are a group of heterogenous 
proteoglycans made up of monosaccharides. The carbohydrate content of LBP comprises 
arabinose, rhamnose, xylose, galactose, glucose, glucoronic acid, galacturonic acid, and mannose 
[107, 108].  LBP can be purified and sub-fractionated by solvents. Different LBP fractions can 
have diverse biological effects [109, 110], although structure-function analysis has yet to be 
performed. The amino acid content of LBP may be important for its biological activities. Yu and 
colleagues showed that its anti-A toxicity is lost when its amino acids are destroyed with strong 
acid [107]. 
 The neuroprotective effects of LBP are not specific to a particular disease. Three 
characteristics of LBP may explain its biological effects on neurons. Firstly, the ability of LBP to 
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suppress the activation of stress kinases under pathological conditions. In vitro data from our 
laboratory showed that LBP has potent inhibitory effects on pro-apoptotic stress kinases such as 
c-Jun N-terminal kinase (JNK), double-stranded RNA-dependent protein kinase (PKR) and 
extracellular signal-regulated kinase (ERK) [97, 110, 111]. Activation of stress kinases are 
common mechanisms leading to neurodegeneration in AD, PD and AMD [112-114]. Suppression 
of the activities of these kinases is responsible for the protective effects of LBP against 
glutamate, A peptide, dithiothreitol (DTT, an endoplasmic reticulum stress inducer), and 
homocysteine-induced toxicity of neurons [97, 110, 111, 115].  
 Secondly, the anti-oxidant properties of LBP may contribute to its neuroprotective 
effects. LBP can increase the activities of anti-oxidative enzymes in peripheral systems [116-
118]. There are few studies on the effects of LBP on neurons. Li and colleagues reported that oral 
administration of LBP reduced neuronal damage and oxidative stress in a retinal 
ischæmic/reperfusion injury model. The levels of lipid peroxidation in the retina were markedly 
reduced in the LBP-treated group [119]. Since this model involves the disruption of the blood-
retina barrier, it may not totally reflect the situation on human chronic neurodegenerative 
diseases. In chronic glaucoma experimental model which does not have leakage of blood-retina 
barrier, oral administration of LBP can rescue retinal cells from apoptotic cell death. It is 
uncertain if the protective effects of LBP in the chronic glaucoma model are through an anti-
oxidative mechanism [120]. Nevertheless, oxidative damage in the retina is a common aspect of 
ocular neurodegeneration, hence the anti-oxidant effects of LBP has the potential to play a 
neuroprotective role in AMD.   
 Up-regulation of survival pathways is the third neuroprotective mechanism. In a cell 
culture model of AD, an alkaline fraction of LBP was protective against A-induced toxicity 
through up-regulation of the Akt pathway [121]. In an ocular hypertension model which mimics 
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human glaucoma, oral administration of LBP to rats up-regulated the neuronal survival signal 
B2-crystallin and prevented neuronal cell loss [122]. 
3.2.2 Indirect effects of big molecules- modulation on the disease risk factors and the immunity 
 As shown in Table 1, age-related neurodegenerative diseases share a number of risk 
factors. Modulation of these risk factors can delay disease onset or slow down their progression. 
In this section, we discuss the use of polysaccharides to antagonize deleterious effects of risk 
factors for AD, PD and AMD. 
(A) Anti-depressive effects  
 Depression is common among AD and PD patients; it occurs in about 20 to 50% of AD 
patients and 45% of PD patients [123, 124]. Experimentally, daily injection of corticosterone 
elevates its plasma levels in rats and induces depression-like behaviors. Zhang et al. reported that 
oral administration of LBP attenuated the depression-like behavior, probably by promoting 
neurogenesis in the hippocampus [125]. Oligosaccharides from the medicinal herb Morinda 
officinalis also exhibit anti-depression properties. In a cell culture model of depression, 
polysaccharide from M. officinalis (MP-1) reduced the corticosterone-induced death of PC12 
cells. MP-1 attenuated the overload of intracellular calcium ion and down-regulated the 
expression of mRNA for nerve growth factor (NGF) [126, 127]. Chemical analysis reveals that 
MP-1 is an insulin-type  fructan with simple linear (2 → 1)-linked structure, and that its 
glucose/fructose ratio is 1:21 [128].  
(B) Hypoglycæmic effects  
 Elevated blood glucose levels in diabetes mellitus can accelerate the progression of 
neurodegeneration. The hypoglycæmic activities of tea polysaccharides have been reported. 
Diabetic mice treated with crude tea polysaccharides, or a tea polysaccharides fraction, had 
significantly lower fasting blood glucose and glycosylated serum protein than their control 
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counterparts. A 100-120 kDa fraction with galactopyranose in the backbone and arabinofuranose 
units in side branches accounted for the hypoglycæmic activity. It was suggested that the 
arabinogalactan proteins in this fraction were important for the biological activity [129]. 
Arabinogalactan proteins are proteoglycans with a high content of arabinose and galactose 
monosaccharides but less than 10% protein. LBP is also rich in arabinose and galactose and has 
hypoglycæmic effects [130]. An early study identified the structural characteristics of several 
arabinoglactan-protein extracted from the fruits of Lycium chinense Mill (a closed related species 
to L. barbarum [131]. It is possible that these arabinoglactan-proteins are responsible for the 
hypoglycæmic activity. 
(C) Immunomodulation effects 
 The immune system can serve as a link between the periphery and the CNS. Systemic 
inflammation can affect the progression of neurodegenerative diseases [132, 133]. 
Polysaccharides that can modulate the immune responses and reduce inflammation may therefore 
be beneficial. We have demonstrated that LBP from L. barbarum can attenuate the activation of 
microglia in the retina in glaucoma [134]. Anti-inflammatory effects of polysaccharides from 
medicinal plants such as Cryptoporus volvatus have been reported [135]. Many non-starch 
polysaccharides found in plants can elicit direct immunomodulatory effects. These 
polysaccharides bind to glycan-binding receptors expressed on dendritic cells, which are the 
immune cells in the peripheral circulation responsible for antigen presentation. Through this 
binding, the polysaccharides can modify signals from other pattern-recognition receptors, such as 
Toll-like receptors, on dendritic cells. This modification alters the effectiveness of both innate 
and adaptive immune responses [136]. Not all polysaccharides inhibit immune responses. We 
have shown that polysaccharides isolated from Prunella vulgaris L. can stimulate 
monocytes/macrophages and microglia to produce more free radicals and cytokines [137, 138] 
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4. THE BIOAVAILABILITY AND PERMEABILITY OF NUTRITIONAL 
MOLECULES AT THE BLOOD-BRAIN BARRIER 
 Many cell-culture and animal studies suggest the potential use of polyphenols such as 
flavonoids, stilbenes and polysaccharides in aged-related neurodegenerative diseases. However, 
there are debates on the effectiveness of these compounds in human subjects. Major concerns 
include bioavailability after gastrointestinal (GI) tract and liver metabolism and permeability 
across the blood-brain barrier (BBB).  
 It is important to note that the natural forms of plants flavonoids do not exist as shown in 
Figure 1b: they are often glycosylated, esterified, or polymerized, giving a huge variety of 
compounds that need further investigation [48, 49]. Nevertheless, it is generally believed that 
most flavonoids are hydrolyzed and conjugated by gut and liver enzymes before entering the 
circulation [50]. Except for the anthocyanins, the majority of circulating flavonoids do not occur 
as their plant forms, but as sulfates, glucuronides, and O-methylated derivatives [139]. These 
derivatives are likely to exhibit different bioactivities from their counterparts in plants, such as a 
reduction of their antioxidative activity [140, 141]. Many in vitro studies have focused on the 
neuroprotective properties of flavonoids that differ from their forms in vivo; caution must be 
exercised when extrapolating from these results. Both intact and/or derivative forms of 
flavonoids such as flavanols (e.g., tea catechins), flavanones (e.g., naringenin) and blueberry 
anthocyanins have been detected in the brain following oral and intravenous administration in 
animals, suggesting that they do pass through the BBB and can possibly take effect in the brain 
[142-144]. The degree of permeability is likely to be governed by several factors, including 
compound lipophilicity [145] and the action of specific transporters on the BBB [146]. However, 
the major questions which still need to be addressed are (1) whether levels attained in vivo are 
comparable to the effective dose used in vitro, and (2) if the in vivo forms also exert similar 
beneficial effects as their natural forms. Moreover, based on the numerous reports on the 
neuroprotective properties in animals [59, 147-151], it is possible that under an in vivo setting, 
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flavonoids, existing mostly as a mixture of metabolized forms, collectively protect the brain 
through a combination of many other important mechanisms that have not been identified. In 
future, it will be beneficial to develop ways to improve the oral bioavailability of flavonoids to 
maximize their benefits to the brain. For example, Scheepens et al have recently proposed the use 
of synergies between oral intakes of different polyphenols to boost bioavailability [152]. 
Additional studies are also need to investigate the usefulness of flavonoids to the human brain. 
In a similar fashion to flavonoids, resveratrol is metabolized into various forms before 
entering the circulation. Natural resveratrol is mainly present in the glycosylated piceid form, 
which greatly enhances its stability against oxidative degradation and raises its solubility and 
absorption from the GI tract [153]. Following absorption, resveratrol is converted into O-
glucuronides and O-sulfates by phase II drug-detoxifying enzymes in the liver [154]. In one 
human study led by Walle et al, following a 25 mg oral dose of resveratrol, as much as 70% of 
this dose was absorbed, with an increase of total resveratrol metabolites in the plasma reaching 2 
uM within 1 hour, but the level of unmodified resveratrol was as low as 5 ng/ml [83]. Moreoever, 
though it is still controversial whether orally administered resveratrol leads to its cerebral 
accumulation to an effective level, Wang et al have shown that an intraperitoneal injection of 
resveratrol (30 mg/kg body weight) in gerbils led to an increase of resveratrol metabolites 
(mostly as glucuronide conjugate form) in the brain, with the highest level, i.e. 400 ng/g of brain 
tissue, observed at the 4th hour, and rapidly declining thereafter [68]. This implies that resveratrol, 
particularly in glucuronide form, is capable of passing through the BBB, although the mechanism 
has yet been elucidated and it is unclear whether the level attained would be sufficient to protect 
the human brain. To date, there is only one report suggesting that orally administered resveratrol 
improves cerebral blood flow in human frontal cortices during cognitive tasks [94]. More work is 
needed to improve the CNS bioavailability of resveratrol and to clarify its effect on the human 
brain. In addition, we cannot rule out the possibility that resveratrol and its metabolites elicit 
protective effects in the brain which differ from those reported from cell culture studies.  
 19 
Alternative route of drug administration can be a possible direction to improve the 
availability of flavonoids and resveratrol in the CNS. Recently, the nasal route of administration 
has gained increasing attention for brain uptake of drugs. Baicalin is a BBB-permeable natural 
flavonoid which has in vivo and in vitro neuroprotective effects against ischemic eye and brain 
damage [155, 156]. Studies on rats show that nasal administration can effectively increase the 
amount of baicalin detected in different brain regions compared with intravenous administration. 
More than half of the administrated baicalin can be transported to the brain via the olfactory 
pathway in 8 hour [157]. Further research should be conducted in human to confirm the 
effectiveness of using nasal administration for delivery of drugs to the brain.  
 There is relatively little information on polysaccharides. Some researchers are skeptical 
that polysaccharides can be developed as CNS drugs because they are less likely to pass through 
the BBB. However, animal studies show that the feeding of polysaccharides can reverse 
neuropathological changes in the eye [119, 122], suggesting that it is possible for these big 
molecules to exhibit effects in the CNS. How can these big molecules modify the CNS 
environment? There are several possibilities: (1) polysaccharides might be transported into the 
CNS by unknown mechanism; (2) their metabolites might reach the CNS; (3) polysaccharides 
might provide their CNS neuroprotection by modulating biological events in the periphery. There 
is insufficient data to draw any conclusion as yet. Low-molecular weight heparin derivatives can 
pass through the BBB to produce their protective effects [20, 158]. These derivatives are 
produced by the depolymerization of the full-length heparin, which has a polysaccharide 
backbone structure [158]. Following on from this, we speculate that some neuroprotective full-
length polysaccharides may be broken down into shorter BBB-permeable derivatives during GI 
tract metabolism. The example of heparin also sheds light on the possibility of synthesizing 
neuroprotective polysaccharide derivatives from natural plant or marine sources. If we can 
identify the structure that is critical for the neuroprotective function, it may be possible to 
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artificially break down the complex long-chain structure to enhance the BBB-permeability and at 
the same time preserve the neuroprotective properties.  
 Currently, most studies on neuroprotective polysaccharides fail to provide information on 
the chemical structure and thus create the major barrier for further characterization of the drug 
metabolism and pharmacokinetics (DMPK) profiles. We believe that this technical problem can 
be overcome. Early studies on the anti-cancer polysaccharides lentinan show that it is possible to 
isolate individual polysaccharide from herbs, characterize their structure and study its DMPK 
properties. An oral formulation of superfine dispersed lentinan is now under clinical trial to 
evaluate its safety and effectiveness in patients with various kinds of cancer [159, 160], 
suggesting that evaluation of the drug metabolism is practically feasible. We encourage 
researchers to conduct more chemical analysis on the potential neuroprotective polysaccharides. 
It will also be worth to study the effects of the metabolite of these compounds.  
 
5. CONCLUSION 
 We have summarized current knowledge on some small molecules such as polyphenols 
and big molecules such as polysaccharides for their potential neuroprotective actions. In the 
small molecules section, we try to link the biological actions of some polyphenols with their 
structures. In the big molecule section, we use several examples to demonstrate that 
polysaccharides are able to modulate neuronal activities and disease-risk factors. Current data 
suggest that many polyphenols and polysaccharides are potent anti-oxidant, anti-inflammatory, 
and immunomodulation agents. Hence, they have potential uses in different age-related 
neurodegenerative diseases. More research is required to enhance the bioavailability and BBB-
permeability of these compounds. 
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Table 1: Risk factors for AD, PD and AMD. 
 
 
Alzheimer’s 
disease 
Parkinson’s 
disease 
Age-related 
macular 
degeneration 
Age Major risk factor 
Depression Relation is not clear, but co-exists in many 
patients [123, 124] 
X 
Smoking Yes [36] X Yes [161] 
Diabetes Yes [37]  Inconsistent data 
[162, 163] 
Weak association 
[164] 
Hyperhomocysteinaemia Yes[165] As a side effect of 
L-Dopa treatment 
[39] 
X 
Hypertension Yes [38] X [163] Yes [133] 
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7. FIGURE LEGENDS 
Figure 1. The chemical structures of the flavonoid backbone (Figure 1a) and various flavonoid 
subclasses (Figure 1b). A. Flavonoids are formed by two benzene rings (rings A and B) 
interconnected by a 3-carbon oxygenated heterocycle (ring C). B. Different flavonoid subclasses 
differ from one another by the saturation of ring C, the presence or absence of the 4-oxo-function, 
and the chemical substitutions on the B and C rings. 
Figure 2. Chemical structures of epigallocatechin gallate (Figure 2a), quercetin (Figure 2b), and 
Naringenin (Figure 2c). A. Epigallocatechin gallate has a gallic group substitution at position 3. 
This group is thought to interact with iron to suppress iron-catalyzed oxidative stress via the 
Fenton reaction. B. Quercetin has strong antioxidant activity which can be attributed to the 
presence of (1) the ortho-dihydroxy groups in ring B, (2) the combination of 2,3 carbon-carbon 
double with the 4-oxo function in ring C, and (3) the possession of the 3-OH and 5-OH groups 
with the 4-oxo function on the A and C rings. The ortho-hydroxy groups in ring B and the 4 oxo-
function together with 3-OH or 5-OH in rings A and C are also responsible for the iron-chelating 
properties. C. Naringenin is a weaker antioxidant and iron chelator since it lacks many of the key 
structural features mentioned above.  
Figure 3. The chemical structure of the stilbene backbone. Stilbenes can either be in cis or trans 
conformations. In general, the trans isomer is more energetically stable and more biologically 
active. 
Figure 4. The chemical structures of resveratrol (Figure 4a), piceatannol (Figure 4b), and M8 
(Figure 4c). Piceatannol is a monohydroxylated resveratrol derivative with an additional OH 
group at position 3', while M8 is a hexahydroxylated stilbene with additional OH groups at 
positions 3', 5' and 4.  
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